Guardant Health, Inc. (GH): Entry into a Material Definitive Agreement
Guardant Health, Inc. (GH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its inten
- Instrument
- convertible senior notes due 2032
- Gross proceeds
- $500.0 million
- Maturity
- May 15, 2032
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
This is a capital-structure event: GH is raising up to $550M in convertible senior notes due 2032, with redemption features tied to the stock price versus the conversion price, and it intends to use proceeds for partial repurchase of its 0% convertible notes due 2027 plus capped call costs.
Market read
Traders should focus on convertible pricing expectations, dilution/hedge dynamics, and any concurrent 2027 note repurchase terms that could affect near-term equity and credit spreads.
What to watch
The article flags that option counterparties and hedged holders may buy GH shares and unwind hedges around pricing, which can temporarily support the stock even as the financing is announced.
Background
The SEC 8-K Item 1.01/2.03/3.02/8.01 reports Guardant Health’s entry into a material definitive agreement tied to a proposed convertible notes offering and related capped call and repurchase plans.
Ticker impact
Guardant Health plans a $500M convertible notes offering due 2032, with up to $50M greenshoe, plus capped calls and potential 2027 note repurchases.
Likely near-term volatility as markets price the convertible issuance, potential dilution, and any concurrent 2027 note repurchase activity.
The 8-K details the size, structure, conversion/redemption mechanics, and stated intended uses of proceeds, which directly affect GH’s capital structure and equity risk.
Market effects
Precision oncology and biotech issuers may see read-through demand for convertible financing and hedging structures.
US small/mid-cap biotech credit and equity derivatives may experience localized hedging flows around pricing.
Limited direct global impact, but convertible issuance mechanics can influence broader risk sentiment toward growth biotech funding.
Counterpoint
If the capped calls and any 2027 repurchases are executed aggressively, the net equity dilution risk could be more contained than typical convertibles, reducing downside.
Key entities
- companyGuardant Health, Inc.
Subject of the 8-K, proposing a $500M convertible senior notes offering due 2032 with up to $50M additional notes.
- debt_instrument0% convertible senior notes due 2027
Existing convertible debt GH expects to repurchase partially using proceeds from the new offering.
- derivative_hedgeCapped call transactions
Privately negotiated capped call overlays intended to reduce potential dilution upon conversion.

